Click here to get full coverage on Aberdeen Group plc Buys 130,294 Shares of Edgewise Therapeutics, Inc. $EWTX - MarketBeat

Aberdeen Group plc Buys 130,294 Shares of Edgewise Therapeutics, Inc. $EWTX  MarketBeat

Aberdeen Group plc Buys 130,294 Shares of Edgewise Therapeutics, Inc. $EWTX - MarketBeat

Click here to get full coverage on Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society - PR Newswire

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society  PR Newswire

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society - PR Newswire

Click here to get full coverage on Edgewise Therapeutics (EWTX): Exploring Valuation After Positive Long-Term Data on Sevasemten in Muscular Dystrophy Trials - simplywall.st

Edgewise Therapeutics (EWTX): Exploring Valuation After Positive Long-Term Data on Sevasemten in Muscular Dystrophy Trials  simplywall.st

Edgewise Therapeutics (EWTX): Exploring Valuation After Positive Long-Term Data on Sevasemten in Muscular Dystrophy Trials - simplywall.st

Click here to get full coverage on How Investors May Respond To Edgewise Therapeutics (EWTX) Long-Term Sevasemten Data at World Muscle Congress - Yahoo Finance

How Investors May Respond To Edgewise Therapeutics (EWTX) Long-Term Sevasemten Data at World Muscle Congress  Yahoo Finance

How Investors May Respond To Edgewise Therapeutics (EWTX) Long-Term Sevasemten Data at World Muscle Congress - Yahoo Finance

Click here to get full coverage on Goldman Sachs Initiates Coverage of Edgewise Therapeutics (EWTX) with Neutral Recommendation - Nasdaq

Goldman Sachs Initiates Coverage of Edgewise Therapeutics (EWTX) with Neutral Recommendation  Nasdaq

Goldman Sachs Initiates Coverage of Edgewise Therapeutics (EWTX) with Neutral Recommendation - Nasdaq

Click here to get full coverage on Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet - Zacks Investment Research

Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet  Zacks Investment Research

Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet - Zacks Investment Research

Click here to get full coverage on Edgewise Therapeutics (EWTX): Evaluating Valuation as New Long-Term Clinical Data Sparks Investor Interest - Yahoo Finance

Edgewise Therapeutics (EWTX): Evaluating Valuation as New Long-Term Clinical Data Sparks Investor Interest  Yahoo Finance

Edgewise Therapeutics (EWTX): Evaluating Valuation as New Long-Term Clinical Data Sparks Investor Interest - Yahoo Finance

Click here to get full coverage on Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules  PR Newswire

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire

Click here to get full coverage on Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of "Moderate Buy" from Analysts  MarketBeat

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Click here to get full coverage on Edgewise Therapeutics (EWTX): Reviewing Valuation After Recent Momentum Shifts - simplywall.st

Edgewise Therapeutics (EWTX): Reviewing Valuation After Recent Momentum Shifts  simplywall.st

Edgewise Therapeutics (EWTX): Reviewing Valuation After Recent Momentum Shifts - simplywall.st

Click here to get full coverage on How Investors Are Reacting To Edgewise Therapeutics (EWTX) Unveiling Long-Term Data for Sevasemten at WMS 2025 - Sahm

How Investors Are Reacting To Edgewise Therapeutics (EWTX) Unveiling Long-Term Data for Sevasemten at WMS 2025  Sahm

How Investors Are Reacting To Edgewise Therapeutics (EWTX) Unveiling Long-Term Data for Sevasemten at WMS 2025 - Sahm

Click here to get full coverage on Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire

Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights  PR Newswire

Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire

Click here to get full coverage on Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 5.1% - Here's What Happened - MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 5.1% - Here's What Happened  MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 5.1% - Here's What Happened - MarketBeat

Click here to get full coverage on We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate - Yahoo Finance

We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate  Yahoo Finance

We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate - Yahoo Finance

Click here to get full coverage on Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights  PR Newswire

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire

Click here to get full coverage on Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?  Yahoo Finance

Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Click here to get full coverage on Edgewise Therapeutics (NASDAQ:EWTX) Trading 8.5% Higher - Should You Buy? - MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Trading 8.5% Higher - Should You Buy?  MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Trading 8.5% Higher - Should You Buy? - MarketBeat

Click here to get full coverage on 16,500 Stock Options at $14.35: Edgewise Therapeutics Awards Inducement Grants to New Hires - Stock Titan

16,500 Stock Options at $14.35: Edgewise Therapeutics Awards Inducement Grants to New Hires  Stock Titan

16,500 Stock Options at $14.35: Edgewise Therapeutics Awards Inducement Grants to New Hires - Stock Titan

Click here to get full coverage on Weiss Ratings Reaffirms "Sell (D-)" Rating for Edgewise Therapeutics (NASDAQ:EWTX) - MarketBeat

Weiss Ratings Reaffirms "Sell (D-)" Rating for Edgewise Therapeutics (NASDAQ:EWTX)  MarketBeat

Weiss Ratings Reaffirms "Sell (D-)" Rating for Edgewise Therapeutics (NASDAQ:EWTX) - MarketBeat

Click here to get full coverage on Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - PR Newswire

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)  PR Newswire

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - PR Newswire

Click here to get full coverage on EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data - Nasdaq

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data  Nasdaq

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data - Nasdaq

Click here to get full coverage on Edgewise Therapeutics (NASDAQ:EWTX) Raised to "Hold" at The Goldman Sachs Group - MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Raised to "Hold" at The Goldman Sachs Group  MarketBeat

Edgewise Therapeutics (NASDAQ:EWTX) Raised to "Hold" at The Goldman Sachs Group - MarketBeat

Click here to get full coverage on New Analyst Forecast: $EWTX Given $20.0 Price Target - Quiver Quantitative

New Analyst Forecast: $EWTX Given $20.0 Price Target  Quiver Quantitative

New Analyst Forecast: $EWTX Given $20.0 Price Target - Quiver Quantitative

Click here to get full coverage on Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Exploring A 135.53% Upside Potential - DirectorsTalk Interviews

Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Exploring A 135.53% Upside Potential  DirectorsTalk Interviews

Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Exploring A 135.53% Upside Potential - DirectorsTalk Interviews

Click here to get full coverage on 247K Stock Options: Edgewise Grants Inducement Awards (15K RSUs) to 9 New Hires - Stock Titan

247K Stock Options: Edgewise Grants Inducement Awards (15K RSUs) to 9 New Hires  Stock Titan

247K Stock Options: Edgewise Grants Inducement Awards (15K RSUs) to 9 New Hires - Stock Titan

Click here to get full coverage on All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy - Yahoo Finance

All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy  Yahoo Finance

All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy - Yahoo Finance

Click here to get full coverage on Edgewise Therapeutics CSO sells $25,539 in EWTX stock - Investing.com

Edgewise Therapeutics CSO sells $25,539 in EWTX stock  Investing.com

Edgewise Therapeutics CSO sells $25,539 in EWTX stock - Investing.com

Click here to get full coverage on $EWTX stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$EWTX stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$EWTX stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $40.55 Average Price Target from Analysts - MarketBeat

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $40.55 Average Price Target from Analysts  MarketBeat

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $40.55 Average Price Target from Analysts - MarketBeat

Click here to get full coverage on Edgewise Therapeutics: Upcoming DMD Trial Data May Disappoint (NASDAQ:EWTX) - Seeking Alpha

Edgewise Therapeutics: Upcoming DMD Trial Data May Disappoint (NASDAQ:EWTX)  Seeking Alpha

Edgewise Therapeutics: Upcoming DMD Trial Data May Disappoint (NASDAQ:EWTX) - Seeking Alpha

Click here to get full coverage on EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm  Business Wire

EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Click here to get full coverage on Breakthrough Muscular Dystrophy Treatment: Edgewise's Sevasemten Shows Disease Stabilization in Key Trials - Stock Titan

Breakthrough Muscular Dystrophy Treatment: Edgewise's Sevasemten Shows Disease Stabilization in Key Trials  Stock Titan

Breakthrough Muscular Dystrophy Treatment: Edgewise's Sevasemten Shows Disease Stabilization in Key Trials - Stock Titan

Click here to get full coverage on Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock - PR Newswire

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock  PR Newswire

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock - PR Newswire

Click here to get full coverage on Edgewise Therapeutics Grants $1.2M Stock Options Package: New Hires Get Equity at $14.26 Per Share - Stock Titan

Edgewise Therapeutics Grants $1.2M Stock Options Package: New Hires Get Equity at $14.26 Per Share  Stock Titan

Edgewise Therapeutics Grants $1.2M Stock Options Package: New Hires Get Equity at $14.26 Per Share - Stock Titan

Click here to get full coverage on RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $49 - 富途牛牛

RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $49  富途牛牛

RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $49 - 富途牛牛

Click here to get full coverage on Edgewise stock falls on sevasemten trial data (EWTX:NASDAQ) - Seeking Alpha

Edgewise stock falls on sevasemten trial data (EWTX:NASDAQ)  Seeking Alpha

Edgewise stock falls on sevasemten trial data (EWTX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Here's Why We're Not At All Concerned With Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation - simplywall.st

Here's Why We're Not At All Concerned With Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation  simplywall.st

Here's Why We're Not At All Concerned With Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation - simplywall.st

Click here to get full coverage on Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On (EWTX) - Seeking Alpha

Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On (EWTX)  Seeking Alpha

Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On (EWTX) - Seeking Alpha

Click here to get full coverage on Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More - Nasdaq

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More  Nasdaq

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More - Nasdaq

Click here to get full coverage on Breakthrough: First-Ever Becker Muscular Dystrophy Treatment Shows 3-Year Disease Stabilization - Stock Titan

Breakthrough: First-Ever Becker Muscular Dystrophy Treatment Shows 3-Year Disease Stabilization  Stock Titan

Breakthrough: First-Ever Becker Muscular Dystrophy Treatment Shows 3-Year Disease Stabilization - Stock Titan

Click here to get full coverage on Muscle Disease Leader Edgewise Therapeutics Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan

Muscle Disease Leader Edgewise Therapeutics Set for Key Goldman Sachs Healthcare Conference Presentation  Stock Titan

Muscle Disease Leader Edgewise Therapeutics Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan

Click here to get full coverage on Edgewise Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com

Edgewise Therapeutics stock initiated with Buy rating at H.C. Wainwright  Investing.com

Edgewise Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com

Click here to get full coverage on Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - PR Newswire

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time  PR Newswire

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - PR Newswire

Click here to get full coverage on $EWTX stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

$EWTX stock is up 8% today. Here's what we see in our data.  Quiver Quantitative

$EWTX stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall - Sahm

No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall  Sahm

No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall - Sahm

Click here to get full coverage on Edgewise Therapeutics stock holds at $16 target amid trial concerns - Investing.com

Edgewise Therapeutics stock holds at $16 target amid trial concerns  Investing.com

Edgewise Therapeutics stock holds at $16 target amid trial concerns - Investing.com

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX - PR Newswire

Click here to get full coverage on What drives EWTX stock price - Support and Resistance Levels & Exceptional Growth Portfolio - earlytimes.in

What drives EWTX stock price - Support and Resistance Levels & Exceptional Growth Portfolio  earlytimes.in

What drives EWTX stock price - Support and Resistance Levels & Exceptional Growth Portfolio - earlytimes.in

Click here to get full coverage on H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $42 - 富途牛牛

H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $42  富途牛牛

H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $42 - 富途牛牛

Click here to get full coverage on Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire

Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm  GlobeNewswire

Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire

Click here to get full coverage on Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - Business Wire

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights  Business Wire

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - Business Wire

Click here to get full coverage on Edgewise Therapeutics CEO Kevin Koch sells $106k in shares - Investing.com

Edgewise Therapeutics CEO Kevin Koch sells $106k in shares  Investing.com

Edgewise Therapeutics CEO Kevin Koch sells $106k in shares - Investing.com

Click here to get full coverage on Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference - PR Newswire

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference  PR Newswire

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference - PR Newswire

Click here to get full coverage on Earnings Preview: EWTX to Report Financial Results Pre-market on August 07 - 富途牛牛

Earnings Preview: EWTX to Report Financial Results Pre-market on August 07  富途牛牛

Earnings Preview: EWTX to Report Financial Results Pre-market on August 07 - 富途牛牛

Click here to get full coverage on Edgewise reports positive results for muscular dystrophy drug - Investing.com

Edgewise reports positive results for muscular dystrophy drug  Investing.com

Edgewise reports positive results for muscular dystrophy drug - Investing.com

Click here to get full coverage on Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged - Investor's Business Daily

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged  Investor's Business Daily

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged - Investor's Business Daily

Click here to get full coverage on Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development - Business Wire

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development  Business Wire

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development - Business Wire

Click here to get full coverage on Edgewise Therapeutics director Peter Thompson acquires $10 million in stock - Investing.com

Edgewise Therapeutics director Peter Thompson acquires $10 million in stock  Investing.com

Edgewise Therapeutics director Peter Thompson acquires $10 million in stock - Investing.com

Click here to get full coverage on Edgewise Therapeutics: A Deep Dive into Recent Performance - StocksToTrade

Edgewise Therapeutics: A Deep Dive into Recent Performance  StocksToTrade

Edgewise Therapeutics: A Deep Dive into Recent Performance - StocksToTrade

Click here to get full coverage on Raymond James initiates Edgewise Therapeutics stock with Strong Buy rating - Investing.com

Raymond James initiates Edgewise Therapeutics stock with Strong Buy rating  Investing.com

Raymond James initiates Edgewise Therapeutics stock with Strong Buy rating - Investing.com

Click here to get full coverage on Goldman Sachs initiates Edgewise Therapeutics stock with Neutral rating - Investing.com

Goldman Sachs initiates Edgewise Therapeutics stock with Neutral rating  Investing.com

Goldman Sachs initiates Edgewise Therapeutics stock with Neutral rating - Investing.com

Click here to get full coverage on Edgewise Therapeutics Executive Makes a Major Stock Move! - TipRanks

Edgewise Therapeutics Executive Makes a Major Stock Move!  TipRanks

Edgewise Therapeutics Executive Makes a Major Stock Move! - TipRanks

Click here to get full coverage on Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025 - PR Newswire

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025  PR Newswire

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025 - PR Newswire

Click here to get full coverage on Edgewise Therapeutics Prices 9.9 Mln Offering At $20.13/shr; Stock Fell In Pre-market - Nasdaq

Edgewise Therapeutics Prices 9.9 Mln Offering At $20.13/shr; Stock Fell In Pre-market  Nasdaq

Edgewise Therapeutics Prices 9.9 Mln Offering At $20.13/shr; Stock Fell In Pre-market - Nasdaq

Click here to get full coverage on Edgewise shares slide amid trial and stock news - The Pharma Letter

Edgewise shares slide amid trial and stock news  The Pharma Letter

Edgewise shares slide amid trial and stock news - The Pharma Letter

Click here to get full coverage on Edgewise reports promising HCM trial results for EDG-7500 - Investing.com

Edgewise reports promising HCM trial results for EDG-7500  Investing.com

Edgewise reports promising HCM trial results for EDG-7500 - Investing.com

Click here to get full coverage on This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday  Benzinga

EWTX

Price Chart

Key Statistics

Technicals

About EWTX

Latest News

Aberdeen Group plc Buys 130,294 Shares of Edgewise Therapeutics, Inc. $EWTX - MarketBeat

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society - PR Newswire

Edgewise Therapeutics (EWTX): Exploring Valuation After Positive Long-Term Data on Sevasemten in Muscular Dystrophy Trials - simplywall.st

Advanced Charts

Top Gainers

Top Losers